Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Arcturus Therapeutics ( (ARCT) ) just unveiled an announcement.
On June 30, 2025, Arcturus Therapeutics announced positive interim results from Phase 2 studies of ARCT-810, an mRNA therapeutic for treating OTC deficiency. The studies showed significant reductions in glutamine levels and improvements in urea cycle function, with ARCT-810 being safe and well tolerated. These findings suggest a promising path forward for addressing an unmet medical need in OTC deficiency, potentially leading to a pivotal study.
The most recent analyst rating on (ARCT) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Arcturus Therapeutics stock, see the ARCT Stock Forecast page.
Spark’s Take on ARCT Stock
According to Spark, TipRanks’ AI Analyst, ARCT is a Neutral.
Arcturus Therapeutics’ stock score reflects a challenging financial performance characterized by consistent net losses and declining revenues, which weigh heavily on its overall score. However, technical indicators and recent earnings call provide some positive momentum. Corporate events demonstrate strong shareholder support, but the high-risk nature of the biotechnology sector and current valuation metrics remain key concerns.
To see Spark’s full report on ARCT stock, click here.
More about Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc. is a commercial messenger RNA medicines company focused on developing infectious disease vaccines and opportunities within liver and respiratory rare diseases.
Average Trading Volume: 469,320
Technical Sentiment Signal: Sell
Current Market Cap: $361.5M
For a thorough assessment of ARCT stock, go to TipRanks’ Stock Analysis page.